Published on
Apr 9, 2026
Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic
2025 was a slow year for IPOs, with only eight companies going public—the fewest in the industry’s post-pandemic era. “We are likely in/entering a more discerning IPO marketplace where drug innovators with proven, later-stage assets/programs will …
Source:
BioSpace
-
Pending
